Zydus Lifesciences stock showed positive momentum, trading up over 2% in early market hours on February 6, 2025, following the announcement of robust Q3FY25 results. The company reported a 30% rise in consolidated net profit, reaching ₹1,023 crore compared to ₹789 crore in Q3 FY24. The robust performance was fueled by growth in both domestic and US markets.
Key Highlights of Q3FY25 Results:
- Revenue from Operations: ₹5,269 crore, up 17% YoY from ₹4,505 crore in Q3FY24.
- EBITDA: ₹1,387 crore, compared to ₹1,102 crore in the previous year.
- EBITDA Margin: Improved to 26.3% from 24.5%, a 200-basis point increase.
- Net Profit: ₹1,023 crore, marking a 30% growth YoY.
- Forex Gains: ₹183 crore, significantly higher than ₹21 crore in Q3FY24.
Stock Performance
Zydus Lifesciences shares opened at ₹997, gaining 2.05% in early trading hours.
Management Commentary
Sharvil Patel, Managing Director, expressed optimism about the company's growth trajectory:
"We are pleased with the sustained growth momentum across our businesses, which keeps us on track to achieve our fiscal 2025 goal of double-digit growth with improved profitability. Our robust portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in international markets position us well for future growth”.
Summary
In summary, Zydus Lifesciences delivered a strong Q3FY25 performance, driven by robust growth in both domestic and US markets. The company reported a 30% YoY surge in net profit to ₹1,023 crore, supported by a 17% rise in revenue and improved EBITDA margins. Forex gains also significantly contributed to profitability. Following the results, the stock gained over 2% in early trading, reflecting investor optimism. Management remains confident in sustaining growth, emphasizing strategic execution in key markets to drive future performance.
Easy & quick
Leave A Comment?